First universal newborn screening program for severe combined immunodeficiency in Europe. Three-years’ experience in Catalonia
e202012153
Keywords:
Newborn screening, Severe combined immunodeficiency, TREC, SCID, PNP deficiency, Catalonia Newborn Screening ProgramAbstract
Severe combined immunodeficiency (SCID), the most severe form of T-cell immunodeficiency, can be screened at birth by quantifying T-cell receptor excision circles (TREC) in dried blood spot (DBS) samples. Early detection of this condition speeds up the establishment of appropriate treatment and increases the patient’s life expectancy. Newborn screening for SCID started in January 2017 in Catalonia, the first Spanish and European region to universally include this testing. The results obtained in the first three years and a half of experience (January 2017 – June 2020) are shown here, using EnLite Neonatal TREC kit (Perkin Elmer) with 20 copies/µL as TREC detection cutoff. Of 222,857 newborns screened, 48 tested positive: three patients were diagnosed with SCID (incidence 1:74,285); 17 patients had clinically significant T-cell lymphopenia (non-SCID) with an incidence of 1 in 13,109 newborns; twenty two patients were considered false-positive cases because of an initially normal lymphocyte count with normalization of TREC between 3 and 6 months of life; one case had transient lymphopenia due to an initially low lymphocyte count with recovery in the following months; and five patients are still under study.
The results obtained provide further evidence of the benefits of including this disease in newborn screening programs. Even longer follow-up could be necessary to define the exact incidence of SCID in Catalonia.
Downloads
References
Van der Burg M, Mahlaoui N, Gaspar HB, Pai SY. Universal Newborn Screening for Severe Combined Immunodeficiency (SCID). Front Pediatr. 2019;7:373.
Modell V, Knaus M, Modell F. An analysis and decision tool to measure cost benefit of newborn screening for severe combined immunodeficiency (SCID) and related T-cell lymphopenia. Immunologic Research. 2014 Oct;60(1):145-152.
Van der Ploeg C, Blom M, Bredius R, van der Burg M, Schielen P, Verkerk PH et al. Cost-effectiveness of newborn screening for severe combined immunodeficiency. European journal of pediatrics. 2019;178(5):721-729.
Puck JM. Newborn screening for severe combined immunodeficiency and T-cell lymphopenia. Immunol Rev. 2019; 287(1):241-252.
Audrain M, Léger A, Hémont, Mirallié S, Cheillan D, Rimbert MGM et al. Newborn Screening for Severe Combined Immunodeficiency: Analytic and Clinical Performance of the T Cell Receptor Excision Circle Assay in France (DEPISTREC Study). J Clin Immunol. 2018; 38(7):778-786.
Kwan A, Abraham RS, Currier R, Brower A, Andruszewski K, Abbott JK et al. Newborn screening for severe combined immunodeficiency in 11 screening programs in the United States. JAMA. 2014; 312(7):729-38.
Buckley R, Schiff SE, Schiff RI, Markert ML, Williams LW, Roberts JL et al. Hematopoietic stem-cell transplantation for the treatment of severe combined immunodeficiency. N. Engl. J. Med. 1999;340:508-516.
Chan K, Puck JM. (2005). “Development of a population-based screening for severe combined immunodeficiency”. J. Allergy Clin. Immunol. 115: 391-398.
Martin-Nalda A, Cueto-González AM, Argudo-Ramírez A, Marín-Soria JL, Martínez-Gallo M, Colobran R et al. Identification of 22q11.2 deletion syndrome via newborn screening for severe combined immunodeficiency. Two years’ experience in Catalonia (Spain). Mol Genet Genomic Med. 2019;7(12):e1016.
King J, Hammarström L. Newborn Screening for Primary Immunodeficiency Diseases: History, Current and Future Practice. J Clin Immunol. 2018;38:56-66.
Routes J, Verbsky J. Newborn Screening for Severe Combined Immunodeficiency. Curr Allergy Asthma Rep. 2018; 18(6):34.
Argudo-Ramírez A, Martín-Nalda A, Marín-Soria JL, López-Galera RM, Pajares-García S, González de Aledo Castillo JM et al. “First universal newborn screening program for severe combined immunodeficiency in Europe. Two-years’ experience in Catalonia (Spain)”. Front Immunol. 2019;10:2406.
Rechavi E, Lev A, Simon AJ, Stauber T, Daas S, Saraf-Levy T et al. First Year of Israeli Newborn Screening for Severe Combined Immunodeficiency – Clinical Achievements and Insights. Front. Immunol. 2017;8:1448.
Audrain M, Léger A, Hémont, Mirallié SM, Cheillan D, Rimbert MGM et al. Newborn Screening for Severe Combined Immunodeficiency: Analytic and Clinical Performance of the T Cell Receptor Excision Circle Assay in France (DEPISTREC Study). J Clin Immunol. 2018; 38(7):778-786.
Blom M, Pico-Knijnenburg I, Sijne-van Veen M, Boelen A, Bredius RGM, van der Buerg M et al. An evaluation of the TREC assay with regard to the integration of SCID screening into the Dutch newborn screening program. Clin Immunol. 2017; 180:106-10.
Adams SP, Rashid S, Premachandra T, Harvey K, Ifederu A,Wilson MC et al. Screening of neonatal UK dried blood spots using a duplex TREC screening assay. J Clin Immunol. 2014; 34:323-30.
Van der Spek J, Groenwold RHH, van der Burg M, van Montfrans JM. TREC based newborn screening for severe combined immunodeficiency disease: a systematic review. J Clin Immunol. 2015; 35:416-30.
Barbaro M, Ohlsson A, Borte S, Jonsson S, Zetterström RH, King J et al. Newborn Screening for Severe Primary Immunodeficiency Diseases in Sweden – a 2-Years Pilot TREC and KREC Screening Study. J Clin Immunol. 2017; 37:51-60.
Nourizadeh M, Shakerian L, Borte S, Fazlollahi M, Badalzadeh M, Houshmand M et al. Newborn screening using TREC/KREC assay for severe T and B cell lymphopenia in Iran. Scand J Immunol. 2018; 88:e12699.
De Felipe B, Olbrich P, Lucenas JM, Delgado‐Pecellin C, Pavon-Delgado A, Marquez J et al. Prospective neonatal screening for severe T and B-lymphocyte deficiencies in Seville. Pediatr Allergy Immunol. 2016;27:70-77.
Borte S, Wang N, Oskarsdóttir S, von Döbeln U, Hammarström L. Newborn screening for primary immunodeficiencies: beyond SCID and XLA. Ann N Y Acad Sci. 2011; 1246:118-30.
Borte S, Puck J, Lorey F, McGhee SA, Hershfield MS, Fasth A et al. KRECs but not TRECs identify patients with delayed-onset adenosine deaminase (ADA) deficiency in neonatal screening. J Clin Immunol. 2013; 33:673.
Downloads
Published
How to Cite
Issue
Section
Categories
License
Copyright (c) 2020 Ana Argudo Ramírez, Andrea Martín Nalda, José Luis Marín Soria, Rosa María López Galera, José Manuel González de Aledo Castillo, Sonia Pajares García, Jacques G. Rivière, Mónica Martínez Gallo, Roger Colobran, Alba Parra Martínez, Antonia Ribes Rubio, Rosa María Fernández Bardon, Laia Asso Ministral, Blanca Prats Viedma, Judit García Villoria, Pere Soler Palacín
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Usted es libre de:
Compartir — copiar y redistribuir el material en cualquier medio o formato.
La licenciante no puede revocar estas libertades en tanto usted siga los términos de la licencia.
Bajo los siguientes términos:
Atribución — Usted debe dar crédito de manera adecuada , brindar un enlace a la licencia, e indicar si se han realizado cambios. Puede hacerlo en cualquier forma razonable, pero no de forma tal que sugiera que usted o su uso tienen el apoyo de la licenciante.
NoComercial — Usted no puede hacer uso del material con propósitos comerciales.
SinDerivadas — Si remezcla, transforma o crea a partir del material, no podrá distribuir el material modificado.
No hay restricciones adicionales — No puede aplicar términos legales ni medidas tecnológicas que restrinjan legalmente a otras a hacer cualquier uso permitido por la licencia.
Avisos:
No tiene que cumplir con la licencia para elementos del material en el dominio público o cuando su uso esté permitido por una excepción o limitación aplicable.
No se dan garantías. La licencia podría no darle todos los permisos que necesita para el uso que tenga previsto. Por ejemplo, otros derechos como publicidad, privacidad, o derechos morales pueden limitar la forma en que utilice el material.
